- $231.78m
- $106.61m
Brief: Palisade Bio Further Strengthens Balance Sheet With Early Exercise Of Warrants Resulting In Cash Proceeds Of $4.9 Million
Palisade Bio soars on stock offering
U.S. STOCKS ON THE MOVE-Silo Pharma, Meta Platforms, Campbell Soup
Brief: Palisade Bio Announces $2.5 Million Registered Direct Offering And Concurrent Private Placement Priced Above Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Meta Platforms, China ADRs, Adagene
Palisade Bio rises on 'sufficient' trial data for bowel function drug
Brief: Palisade Bio Gives Update On U.S. Phase 2 Study Evaluating LB1148
U.S. STOCKS ON THE MOVE-Caterpillar, Coinbase, WW International
U.S. STOCKS ON THE MOVE-Best Buy, Warner Music, Abercrombie & Fitch
Palisade Bio shares more than double over 'fast track' tag for bowel function drug
Palisade Bio soars on 'fast track' tag for bowel function drug
Brief: Palisade Bio Is Granted Fast Track Designation From The U.S. Food And Drug Administration For LB1148 For Accelerated Return Of Bowel Function Following GI Surgery
Brief: Palisade Bio Announces Reverse Stock Split
Brief: Palisade Bio Reports Third Quarter 2022 Financial Results, Provides Business Update
Palisade Bio Inc reports results for the quarter ended in September - Earnings Summary
Palisade Bio Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Palisade Bio Inc - Board Appoints JD Finley To Interim Chief Executive Officer
Brief: Palisade Bio Streamlines Operations And Identifies Capital Efficiencies To Focus All Resources On Advancement Of Lead Clinical Program, Lb1148
Brief: Mitchell Kopin Reports 9.99% Passive Stake In Palisade Bio